within Pharmacolibrary.Drugs.C_CardiovascularSystem.C05A_AgentsForTreatmentOfHemorrhoidsAndAnalFissuresForTopicalUse.C05AA06_Fluorometholone;

model Fluorometholone
  extends Pharmacolibrary.Drugs.ATC.C.C05AA06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C05AA06</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fluorometholone is a synthetic corticosteroid primarily used as an ophthalmic agent to treat inflammatory eye conditions, such as allergic conjunctivitis and uveitis. It has anti-inflammatory properties and is available in eye drop formulations. Fluorometholone is approved for medical use in many countries and remains in clinical practice primarily for ophthalmic indications.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical ophthalmic administration in adult humans, as specific human PK data are not available from published sources. Parameters are intuitively estimated based on corticosteroid class and ophthalmic pharmacokinetics.</p><h4>References</h4><ol><li><p>Baba, K, et al., &amp; Nishida, K (2021). The generation of fluorometholone nanocrystal eye drops, their metabolization to dihydrofluorometholone and penetration into rabbit eyes. <i>International journal of pharmaceutics</i> 592 120067–None. DOI:<a href=\"https://doi.org/10.1016/j.ijpharm.2020.120067\">10.1016/j.ijpharm.2020.120067</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33189813/\">https://pubmed.ncbi.nlm.nih.gov/33189813</a></p></li><li><p>Lee, H, et al., &amp; Kim, SW (2023). Corticosteroid-Antibiotic Interactions in Bacteria that Cause Corneal Infection. <i>Translational vision science &amp; technology</i> 12(5) 16–None. DOI:<a href=\"https://doi.org/10.1167/tvst.12.5.16\">10.1167/tvst.12.5.16</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37184498/\">https://pubmed.ncbi.nlm.nih.gov/37184498</a></p></li><li><p>Schoenwald, RD, et al., &amp; Chien, DS (1987). Ophthalmic bioequivalence of steroid/antibiotic combination formulations. <i>Biopharmaceutics &amp; drug disposition</i> 8(6) 527–548. DOI:<a href=\"https://doi.org/10.1002/bdd.2510080605\">10.1002/bdd.2510080605</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3427210/\">https://pubmed.ncbi.nlm.nih.gov/3427210</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fluorometholone;
